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CASE REPORT
Loperamide cardio toxicity: a case report of turning bowels 
and twisting points
Katherine Rizzolo MD,1 Ryan Best MD,2 Tammi Schaeffer DO, FACEP, FACMT, FAACT,3 John Erickson 
MD FACP1
1Department of Internal Medicine, Maine Medical Center, Portland, ME, 2Department of Critical Care Medicine, Maine 
Medical Center, Portland, ME, 3Department of Emergency Medicine, Maine Medical Center, Portland, ME
Introduction:  Loperamide is a synthetic mu-receptor agonist used for treating diarrhea. Recently, it has been illicitly 
used for a euphoric high or to diminish symptoms of opiate withdrawal. In case reports, loperamide 
abuse has been associated with cardiac arrhythmias, most notably, ventricular tachycardia and torsades 
de pointes, presumably related to prolongation of the QTc.
Clinical findings:  A 32-year-old male with a history of opioid use disorder presented unresponsive, and was found to have 
polymorphic ventricular tachycardia, torsades de pointes, prolonged QTc and QRS, and transient left 
ventricular dysfunction.
 When his mental status cleared, the patient reported taking up to 40 pills (80 mg) of loperamide daily 
with the intent of alleviating symptoms of opiate withdrawal. This misuse was believed to cause his QTc 
prolongation, leading to cardiac toxicity and subsequent dysrhythmia. The patient initially required a 
temporary pacing wire, which was removed on hospital day 3. He was discharged with a prescription 
for suboxone and duloxetine, and he was connected with specialists to address his substance use 
disorder.
Conclusions:  We describe a patient with cardiac toxicity associated with loperamide misuse. In the wake of the current 
opioid epidemic, the occurrence of loperamide toxicity may increase. It is important for physicians to 
understand and identify the life-threatening effects of loperamide toxicity to properly diagnose and 
manage the condition.
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CASE PRESENTATION
A 32-year-old male with a history of opiate use 
disorder presented to an outside emergency 
department after being found unresponsive in 
his running car. After 1 hour, he developed non-
sustained ventricular tachycardia (VT) followed 
by wide-complex bradycardia with first-degree 
block. This bradycardia converted to polymorphic 
VT requiring intravenous bicarbonate, single-
synchronous cardioversion, and amiodarone. He 
then had a short, self-terminating episode of torsades 
de pointes (Figure 1) followed by bradycardia with a 
QTc persistently over 600 msec and a QRS of 167 
msec. He was transferred to the cardiac intensive 
care unit of this hospital for immediate placement of 
a temporary transvenous pacer with the purpose of 
overdrive pacing.
The results of his initial exam only noted arrhythmia, 
altered mental status, and agitation. The initial 
lab results showed a leukocytosis of 14,300/uL, 
troponin-T peak of 0.10 ng/mL (normal <0.01 ng/
mL), and brain natriuretic peptide of 1303 pg/
mL (normal <450 pg/dL). His urine toxicology 
results reflected that the emergency department 
administered midazolam. The echocardiogram 
showed a reduced ejection fraction (30-35%) with 
global wall motion abnormality.
Diagnosis, 
interventions, 
and outcomes:
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After the temporary wire was placed, the patient’s 
mental status cleared. He reported finding internet 
forums suggesting opioid-like effects with high 
doses of loperamide, leading him to take up to 40 
pills (80 mg) daily (recommended upper limit of 
therapeutic dosing: 16 mg/daily). Twenty-four hours 
after presentation, his loperamide level was 34 ng/
mL (normal limit: <5 ng/mL) and his desmethyl 
loperamide level (a loperamide metabolite) was 
250 ng/mL (therapeutic levels: <20 ng/mL).
By hospital day 2, his VT resolved, and his QTc and 
QRS normalized, so the temporary pacemaker was 
removed. On hospital day 3, a repeat transthoracic 
echocardiogram showed normal systolic function. 
He was discharged with suboxone, duloxetine, and 
outpatient follow-up.
DISCUSSION
Loperamide is a synthetic opioid used to slow bowel 
motility in diarrheal illness and is readily available 
over the counter. It acts as a direct agonist at the 
circular and intestinal muscles via the mu-opioid 
receptor. At therapeutic doses, loperamide has 
low oral bioavailability and nominally penetrates 
the blood-brain barrier. Thus, it was believed to 
have little potential for abuse.1 Recently, many 
reports described cases in which loperamide was 
misused recreationally or to alleviate symptoms of 
withdrawal.
Non-medical or non-prescribed use of loperamide 
is increasing as information on the internet 
regarding alternative uses continues to uptrend.2 
One study analyzed the occurrence of the search 
term “loperamide” with Google Trends.* The 
analysis showed an increase in the use of the 
search term “loperamide” from 2009 to 2015, 
with an approximate 300% increase from 2011 to 
2015 when combined with terms such as “high” 
or “withdrawal.” The National Poison Database 
System reported a 91% increase in intentional 
loperamide exposures between 2010 and 2015.3 To 
mitigate loperamide misuse, the US Food and Drug 
Administration changed loperamide packaging to 
blister packs to limit large-quantity purchases in 
January 2018.4
Loperamide misuse has been associated with cardiac 
dysrhythmias, such as ventricular fibrillation or 
tachycardia, cardiac arrest, and death.1,5-11 Transient 
left ventricular dysfunction is often observed with 
stress- or tachycardia-induced cardiomyopathy.9,10 
Notably, some cases reported that supratherapeutic 
doses of loperamide can result in onset and an 
increased duration of toxic effects that extend 
beyond the drug’s reported half-life and duration of 
action.11 The proposed mechanism is multifactorial 
via antagonism at cardiac L-type calcium channels, 
delayed rectifier potassium channels, and sodium 
channel blockade. These effects lead to delayed 
duration of action potentials, prolonged QRS, and 
severe prolonged QTc. In addition, loperamide 
inhibits the Nav1.5 sodium channel and the human 
ether-a-go-go (hERG) rectifier potassium channel 
in cloned human myocyte cells, affecting QRS 
and QT prolongation, respectively.12 Interestingly, 
sodium channel blockade may be dose-dependent, 
as the phenomenon occurs only with high levels of 
loperamide.
Diagnosis hinges upon clinical history and 
the presence of arrhythmia at presentation. 
Confirmatory lab testing may take 1-2 weeks. 
Initial treatment should focus on establishing a 
perfusing rhythm, which may require cardioversion 
or temporary overdrive pacing with a pacing wire. 
Isoproterenol has also been suggested but has 
not been well studied. Naloxone has shown some 
efficacy for reversing respiratory depression, 
but it has ineffectively treated arrhythmias.6 With 
aggressive supportive care, most patients improved 
after loperamide was discontinued.5,11
Loperamide’s effect on QTc has been described 
only in case reports; however, the effects of other 
opiates on QTc prolongation have been studied 
in greater detail.13 The predominant mechanism 
involves inhibition of the lkr current.14 Specifically, 
methadone prolongs QTc and is the leading cause 
of medication-associated torsades de pointes.15 
However, the effect of the methadone dose on QTc 
prolongation is mixed.16,17 In contrast, buprenorphine 
has been associated with fewer cases of torsades 
de pointes and QTc prolongation.15 Oxycodone 
has shown QTc prolongation that may be dose-
dependent, but to a lesser degree than methadone.14
This case illustrates the potentially life-threatening 
toxicity associated with loperamide misuse. As 
* This feature reports a normalized line graph that reflects interest in a search topic as a proportion of all Google searches on all 
topics during the specified time and location.
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Figure 1. Admission electrocardiogram illustrating torsades de pointes
opiate prescriptions are reduced in response to the 
current opioid epidemic, loperamide misuse and 
toxicity may increase. Physicians must be aware of 
these dangers, as many dysrhythmias associated 
with loperamide misuse can be unpredictable 
and may be fatal without appropriate treatment. 
Awareness of this condition will support the prompt 
identification of toxicity and treatment of electro-
cardiac abnormalities, reducing mortality and 
improving outcomes.
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